

GlaxoSmithKline have no comments on the Appraisal Consultation Document for the Prophylaxis of Influenza at this time, nor did we notice any factual inaccuracies in the report. We feel the ACD fairly balances the important role of the neuraminidase inhibitors in flu prevention in selected patient groups, against both the need to support the vital work of flu vaccination as a first line strategy, and the need to use NHS resources in a cost-effective manner.

King Regards,

[Redacted]

[Redacted]

[Redacted]

GlaxoSmithKline

[Redacted]

[Redacted]